| 84 | 0 | 56 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 对药学服务经济学评价相关研究进行文献计量和可视化分析，探索其现状、热点和发展趋势。方法 以“pharmacy service”和“economic evaluation”等为检索词检索WOS(Web of Science)数据库（建库至2024年10月10日），收集并分析研究年发文量、发文国家、作者、机构，用CiteSpace软件进行引文突现和关键词检测，使用VOSviewer作关键词共现，分析关键词和研究热点。结果 共纳入428篇文献，美国发文量最高，且与其他国家的合作关系最为密切；中国发文量位居第三。共发现5个聚类，分别是老年患者的社区药学服务和居家药学服务（聚类Ⅰ）；特殊人群，如癌症、急诊、肾脏疾病、移植患者（聚类Ⅱ）；慢病人群的治疗药物管理（聚类Ⅲ）；危重症患者（聚类Ⅳ）；药学干预和用药教育（聚类Ⅴ）。聚类Ⅰ和聚类Ⅱ是近期研究关注点。结论 该研究运用文献计量学方法，系统梳理了药学服务经济学评价领域的研究现状与文献特征，为该领域的深入探索提供了数据支撑与文献参考，并对我国今后开展相关药学服务实践与政策制定具有指导意义。
Abstract：AIM To conduct a bibliometric and visual analysis of studies on the economic evaluation of pharmacy services, exploring the research status, hotspots, and development trends. METHODS Web of Science database was searched as of October 10, 2024, with search terms of "pharmacy service" and "economic evaluation". Data including annual publication amounts, countries, authors, and institutions were collected and analyzed. CiteSpace software was used for burst citation and keyword detection, while VOSviewer was used for keyword co-occurrence analysis to identify research hotspots. RESULTS A total of 428 articles were included. The United States was the country with the highest publication volume and had the closest collaboration with other countries, while China ranked third in publication volume. Keyword co-occurrence analysis identified 5 related clusters: community pharmacy services and home-based pharmacy services for elderly patients(Cluster Ⅰ); pharmacy services for special populations, such as cancer, emergency, renal disease, and transplant patients(Cluster Ⅱ); medication therapy management for chronic disease populations(Cluster Ⅲ); critically ill patients(Cluster Ⅳ); and pharmaceutical interventions and medication education(Cluster Ⅴ). Clusters Ⅰ and Ⅱ were recent areas of research focus. CONCLUSION This study analyzes the characteristics of economic evaluations of pharmacy services in the literature using bibliometric methods, providing references for in-depth research in the field and offering strategic insights to guide the development of pharmacy services in China.
[1]闫婷,伍琳,熊抚辰,等.医疗机构药学服务收费政策落地的关键挑战及优化策略[J].卫生经济研究, 2025, 42(3):51.
[2]范菁,唐昊翔,王银辉,等.闭环式药学监护模式的构建与实践效果评价[J].中国临床药学杂志, 2024, 33(6):418.
[3] KOZMA C M, REEDER C E, SCHULZ R M. Economic, clinical,and humanistic outcomes:a planning model for pharmacoeconomic research[J]. Clin Ther, 1993, 15(6):1121.
[4]阿迪力·吐尔孙,程刚.临床药师提供不同药学服务的经济性研究的系统评价[J].中国药师, 2024, 27(4):674.
[5] SYNNESTVEDT M B, CHEN C M, HOLMES J H. CiteSpaceⅡ:visualization and knowledge discovery in bibliographic databases[J]. AMIA Annu Symp Proc, 2005, 2005:724.
[6] VAN ECK N J, WALTMAN L. Software survey:VOSviewer, a computer program for bibliometric mapping[J]. Scientometrics,2010, 84(2):523.
[7] SMITH W E, MACKEWICZ D W. An economic analysis of the PACE pharmacy service[J]. Am J Hosp Pharm, 1970, 27(2):123.
[8] AVERY A J, RODGERS S, CANTRILL J A, et al. A pharmacistled information technology intervention for medication errors(PINCER):a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis[J]. Lancet, 2012, 379(9823):1310.
[9] JOHNSON J A, BOOTMAN J L. Drug-related morbidity and mortality. A cost-of-illness model[J]. Arch Intern Med, 1995,155(18):1949.
[10] LEAPE L L, CULLEN D J, CLAPP M D, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit[J]. JAMA, 1999, 282(3):267.
[11] SCHUMOCK G T, BUTLER M G, MEEK P D, et al. Evidence of the economic benefit of clinical pharmacy services:1996-2000[J].Pharmacotherapy, 2003, 23(1):113.
[12] GILLESPIE U, ALASSAAD A, HENROHN D, et al. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older:a randomized controlled trial[J]. Arch Intern Med, 2009,169(9):894.
[13] DE RIJDT T, WILLEMS L, SIMOENS S. Economic effects of clinical pharmacy interventions:a literature review.[J] Am J Health Syst Pharm, 2008, 65(12):1161.
[14] CHISHOLM-BURNS M A, GRAFF ZIVIN J S, LEE JK, et al.Economic effects of pharmacists on health outcomes in the United States:a systematic review[J]. Am J Health Syst Pharm, 2010,67(19):1624.
[15] SHEN J, SUN QM, ZHOU XM, et al. Pharmacist interventions on antibiotic use in inpatients with respiratory tract infections in a Chinese hospital[J]. Int J Clin Pharm, 2011, 33(6):929.
[16] JóDAR-SáNCHEZ F, MALET-LARREA A, MARTíN J J, et al.Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain:the conSIGUE program[J]. Pharmacoeconomics, 2015,33(6):599.
[17] BOSMA B E, VAN DEN BEMT P M L A, MELIEF P H G J, et al.Pharmacist interventions during patient rounds in two intensive care units:clinical and financial impact[J]. Neth J Med, 2018,76(3):115.
[18] AL-QUDAH R A, AL-BADRIYEH D, AL-ALI F M, et al. Costbenefit analysis of clinical pharmacist intervention in preventing adverse drug events in the general chronic diseases outpatients[J].J Eval Clin Pract, 2020, 26(1):115.
[19] SCHUMOCK G T, MEEK P D, PLOETZ P A, et al. Economic evaluations of clinical pharmacy services--1988-1995. The Publications Committee of the American College of Clinical Pharmacy[J]. Pharmacotherapy, 1996, 16(6):1188.
[20] TOUCHETTE D R, DOLORESCO F, SUDA K J, et al. Economic evaluations of clinical pharmacy services:2006-2010[J].Pharmacotherapy, 2014, 34(8):771.
[21] PEREZ A, DOLORESCO F, HOFFMAN J M, et al. ACCP:economic evaluations of clinical pharmacy services:2001-2005[J].Pharmacotherapy, 2009, 29(1):128.
[22]张颖,王德礼,陈世财,等.基于Web of Science数据库的社区药学服务文献计量及研究进展[J].临床药物治疗杂志, 2024,22(6):28.
[23] MI X, SU X L, JIN Z Y, et al. Economic evaluations of clinical pharmacy services in China:a systematic review[J]. BMJ Open,2020, 10(1):e034862.
[24] HERLEDAN C, FALANDRY C, HUOT L, et al. Clinical impact and cost-saving analysis of a comprehensive pharmaceutical care intervention in older patients with cancer[J]. J Am Geriatr Soc,2024, 72(2):567.
[25] ZHANG P, LV D, ZHAO J, et al. Evaluation of pharmacists'interventions on drug-related problems and drug costs in patients with cancer pain[J]. Int J Clin Pharm, 2021, 43(5):1274.
[26] WU C W, HUANG Y J, CHEN Y W, et al. Cost-benefit analysis of involving pharmacist for medication therapy management in a heart transplant clinic[J]. Transplant Proc, 2023, 55(2):426.
[27] TABER D J, FLEMING J N, SU Z M, et al. Significant hospitalization cost savings to the payer with a pharmacist-led mobile health intervention to improve medication safety in kidney transplant recipients[J]. Am J Transplant, 2021, 21(10):3428.
[28] BATRAN R A, SABRI N A, ALI I, et al. Cost-effectiveness of the pharmacist-managed warfarin therapy vs. standard care for patients with mechanical mitral valve prostheses:an Egyptian healthcare perspective[J]. Front Cardiovasc Med, 2022, 9:889197.
[29] CHANG J Y, WANG C C, KANG H C, et al. Cost-effectiveness of the pharmacist-assisted warfarin monitoring program at a Medical Center in Taiwan[J]. Int J Qual Health Care, 2017, 29(6):817.
[30] GALLAGHER J, CARTHY S M, WOODS N, et al. Economic evaluation of arandomized controlled trial of pharmac is tsupervized patient self-testing of warfarin therapy[J]. J Clin Pharm Ther, 2015, 40(1):14.
[31] SAOKAEW S, PERMSUWAN U, CHAIYAKUNAPRUK N, et al.Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand[J]. Thromb Res, 2013, 132(4):437.
[32] IBRAHIM D M, SHAWKI M A, SOLAYMAN M H, et al. The impact of clinical pharmacist implemented protocol on albumin utilization and cost in an intensive care unit in Egypt[J]. Front Pharmacol, 2022, 13:825048.
[33] BUCKLEY M S, AGARWAL S K, LANSBURG J M, et al. Clinical pharmacist-led impact on inappropriate albumin utilization and associated costs in general ward patients[J]. Ann Pharmacother,2021, 55(1):44.
[34] BUCKLEY M S, KNUTSON K D, AGARWAL S K, et al. Clinical pharmacist-led impact on inappropriate albumin use and costs in the critically ill[J]. Ann Pharmacother, 2020, 54(2):105.
[35]魏春燕,严知静,何金汗,等.药学服务对重症监护病房患者治疗效果及经济学价值的系统评价[J].中国临床药学杂志, 2024,33(1):48.
基本信息:
DOI：10.19577/j.1007-4406.2025.10.003
中图分类号:R956;G353.1
引用信息:
[1]潘晨,韩强,赵莹,等.基于WOS数据库的药学服务经济学评价文献计量和可视化分析[J].中国临床药学杂志,2025,34(10):734-742.DOI:10.19577/j.1007-4406.2025.10.003.
基金信息:
北京慢性病防治与健康教育研究会（编号MBZX0082024001）; 国家卫生健康委医院药学高质量发展研究项目（编号NIHAYS2302）